39 results about "Prostate cancer risk" patented technology

The present invention is characterised by certain genetic variants being susceptibility variants for prostate cancer. The invention relates to methods of determining increased susceptibility to prostate cancer, as well as methods of determining decreased susceptibility to prostate cancer, using such variants. The invention further relates to kits for determining a susceptibility to prostate cancer.

It has been discovered that certain genetic markers are associated with risk of prostate cancer. The invention describes diagnostic applications for determining a susceptibilty to prostate cancer using such markers, including methods, uses, kits, and computer applications.

The present invention relates to PG1, a gene associated with prostate cancer. The invention provides polynucleotides including biallelic markers derived from PG1 and from flanking genomic regions. Primers hybridizing to these biallelic markers and regions flanking are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and prostate cancer and between a haplotype and prostate cancer. The invention also relates to diagnostic methods of determining whether an individual is at risk for developing prostate cancer, and whether an individual suffers from prostate cancer as a result of a mutation in the PG1 gene.

The present invention provides a method of identifying a subject as having an increased risk of developing prostate cancer, comprising detecting in the subject the presence of various polymorphisms associated with an increased risk of developing prostate cancer.

The present invention provides methods of determining if an individual is at risk for prostate cancer. The methods measures and compares free and/or bound zinc levels in a semen sample or prostatic fluid, including post massage expressed prostatic fluid, in the potential at risk individual with normal levels. A decrease in zinc level is indicative of a risk for prostate cancer.

The invention relates to a method for treating androgen simulated diseases of a subject through delivering a combination containing an effective dose of I Kappa B kinase subunit alpha active inhibitors to the subject who needs treatment, which can also be used for reducing the risk of prostatic cancer of a subject through delivering the combination to the subject with high risk of prostatic cancer. The invention also relates to a method for recognizing a regulator of I Kappa B kinase subunit alpha regulated transcriptional activity. The invention also relates to a method for determining the I Kappa B kinase subunit alpha regulated transcriptional activity in nonhuman mammal test subjects.

The invention discloses a prostatic cancer risk predicting device which comprises an information collecting module, a risk predicting module and a result feedback module. The information collecting module is used for receiving related information and an examination result of a user, the risk predicting module is used for receiving data of the information collecting module, and the result feedback module is used for feeding a result of the risk predicting module back to the user and medical staff. The prostatic cancer risk predicting device is based on a prostatic risk predicting model suitable for Chinese people, so that early prediction of prostatic cancer risk of a patient is facilitated, and the prostatic cancer risk predicting device can prompt prostatic puncture biopsy as soon as possible; in addition, the prostatic cancer risk predicting device can realize background data collection and brings convenience to the medical staff to know information of the patient in details and to diagnosis and treatment. The prostatic cancer risk predicting device is wide in application range, the patient fills in information according to needs completely, and risk value of current prostatic cancer of individuals can be predicted; contact information can be further filled in for the convenience of contact between the medical staff and the patient. The prostatic cancer risk predicting device has great public health significance and economic value.

The invention discloses a device for predicting a prostate cancer risk in prostate aspiration biopsy. The risk of prostate cancer is predicted in advance, prostate biopsy is only carried out on patients is avoided under the condition that missed diagnosis is not increased, and thus unnecessary biopsy of biopsy patients is reduced. According to the technical scheme, related clinical clinicopathologic data of newly-diagnosed prostate aspiration biopsy patients is subjected to retrospective analysis, a prediction nomographic chart of related prediction indexes is established, and accordingly the device convenient to use clinically is designed. By means of the device, clinical doctors can predict the probability of newly-diagnosed prostate aspiration biopsy cancer according to three clinical indexes, namely, prostate health index numerical values, the prostate volume and the age of patients.

A data storage device comprises a memory in which a collection of prostate cancer screening data is stored. The screening data is obtained from a selection of the general male population without medical pre-selection. A device for indicating a risk for a disease of an individual, comprises an indicator for indicating a determined value for said risk. The indicator comprises a risk scale representing a range of values of said risk, and at least one dialler for entering a value of a diagnostic parameter of an individual. The dialler comprises a parameter scale representing a range of values of said diagnostic parameter. The dialler is movable with respect to said indicator such that when a parameter value on said parameter scale is selected, an associated risk value is indicated on said risk scale according to a predetermined mathematical relationship

The invention relates to a method and equipment for predicting postoperative biochemical relapse of a prostate cancer patient. The method comprises the following steps: acquiring clinical pathological data of the prostate cancer patient, wherein the clinical pathology data at least comprise existence of IDC-P, age, NCCN standard prostate cancer risk classification and clinical T stage, and the clinical pathology data has certain correlation with the probability of biochemical recurrence of the prostate cancer patient. According to the clinical pathology data of the prostate cancer patient, based on a pre-trained prognosis model, a prediction probability of biochemical recurrence of the prostate cancer patient within a preset time is obtained. Prediction is performed through the prognosis model, compared with physicians, the prediction efficiency is higher, the prediction accuracy of the prognosis model can be continuously improved along with increase of sample data, and the prediction accuracy is higher compared with the physicians.

The present invention relates to a method for determining a subject having a risk of having developed or developing prostate cancer, which comprises the following steps: a) a step of analyzing the presence/absence or level of mutation in the PCA-1 gene derived from the subject; and b) a step of evaluating the presence/absence or level of the subject's risk of having developed or developing prostate cancer, based on the presence/absence or level of mutation in the PCA-1 gene. According to the determination method of prostate cancer of the present invention, a subject having a risk of having developed or developing prostate cancer can be determined conveniently and highly sensitively. Therefore, the method is effective for the diagnosis of prostate cancer, progress monitoring, prognostic prediction, diagnosis before the onset, carrier diagnosis and the like.